Aetna LMWHs & Thrombin Inhibitors Coverage

Coverage Summary

This policy defines when LMWHs (e.g., enoxaparin, dalteparin, tinzaparin, fondaparinux) and thrombin inhibitors (notably argatroban) are covered versus considered experimental/investigational. Aetna considers these agents medically necessary for multiple VTE prevention and treatment scenarios (including orthopedic and certain oncologic surgeries, inpatient and outpatient DVT/PE treatment, pregnancy-related indications, multiple myeloma prophylaxis, and hospitalized COVID-19 thromboprophylaxis) and specifically covers argatroban for HIT-related prophylaxis/treatment; other listed indications are experimental/investigational when effectiveness is unestablished. The policy includes specific billing guidance referencing HCPCS/CPT/ICD-10 codes for LMWHs and argatroban and notes product-specific J-codes (e.g., J1650, J1645, J0883–J0899) to be used when selection criteria are met.

Policy metadata and review dates

Policy Number0346

PayerAetna

Policy TitleLow-Molecular-Weight Heparins and Thrombin Inhibitors

Effective Date1999-08-11

Last Review2023-05-16

Next Review2024-03-28

StatusCURRENT

Key ActionDefines medical necessity and experimental/investigational indications for LMWHs and thrombin inhibitors, lists dosing summaries and applicable billing/coding; covers indications where LMWH/DTI are medically necessary and when they are investigational.

Medical-Necessity Criteria

Medical Necessity

Aetna considers LMWHs and thrombin inhibitors medically necessary for the following indications when criteria are met:

ANY of the following

Prevention of venous thromboembolism (VTE) for any of the following
- Hip surgery including replacement and hip fracture surgery (for up to 35 days post-operatively)
- Knee surgery including replacement surgery (for up to 2 weeks post-operatively)
- Severely restricted mobility during acute illness: Members at risk of thromboembolic complications due to severely restricted mobility during acute illness (e.g., acute multiple trauma, acute spinal cord injury, acute thrombotic stroke, leg immobilization from ankle or foot trauma)

Experimental and Investigational

Recommended Durations for VTE Prophylaxis

ACCP-derived guidance summarized in the policy recommends prophylaxis duration tied to surgical context and agent: for high-risk nonorthopedic general surgery (major pelvic/abdominal cancer surgery or prior VTE), use LMWH for up to 28 days (Grade 1B); for hip fracture surgery, a minimum 10–14 days is recommended with suggestion to extend up to 35 days in some settings (Grades 1B/2B); for total hip and total knee replacement the minimum is 10–14 days with consideration to extend to 35 days. The appendix also lists alternative agents and grades for these settings (e.g., VKA/warfarin INR goal 2–3, fondaparinux (Arixtra), and DOACs such as rivaroxaban, apixaban, dabigatran) with the comparative durations/grades noted.

Operational Thresholds & Definitions

Policy-specific thresholds

Kawasaki aneurysm size thresholdZ-score ≥ 10 or absolute dimension ≥ 8 mm

MM: VTE risk factors required for LMWH prophylaxis>= 2

Key operational definitions used in the criteria: LMWH = low-molecular-weight heparins (fragments of UFH used subcutaneously, e.g., enoxaparin, dalteparin, tinzaparin, fondaparinux); UFH = unfractionated heparin; DTI = direct thrombin inhibitor (e.g., argatroban, bivalirudin, desirudin, lepirudin); HIT = heparin-induced thrombocytopenia; VTE = venous thromboembolism (DVT and PE); DOAC = direct oral anticoagulant (e.g., apixaban, rivaroxaban); VKA = vitamin K antagonist (warfarin). These terms inform application of the medical necessity and investigational criteria.

Coding

HCPCS codes covered if selection criteria are metHCPCSCovered

J1645	Injection, dalteparin sodium, per 2500 IU
J1650	Injection, enoxaparin sodium, 10 mg
J1652	Injection, fondaparinux sodium, 0.5 mg
J1655	Injection, tinzaparin sodium, 1000 IU

HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered

J9190

Injection, fluorouracil, 500 mg

Other HCPCS codes related to the CPBHCPCS

E0650-E0675	Pneumatic compressor and appliances
J1094	Dexamethasone acetate, IM, 1 mg
J1100	Dexamethasone sodium phosphate, IM, IV, OTH, 1 mg
J7637	Dexamethasone, concentrated form, INH per mg
J7638	Dexamethasone, unit form, INH, per mg
J8540	Dexamethasone, oral, 0.25 mg
J9000	Doxorubicin HCl, IV, 10 mg
Q2050	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg

ICD-10 codes covered if selection criteria are metICD-10Covered

C90.00-C90.02	Multiple myeloma [recent diagnosis receiving thalidomide or lenalidomide]
D68.51-D68.62	Primary and other thrombophilia
I20.0	Unstable angina
I21.4, I22.2	Subendocardial infarction
I21.01-I21.9	Acute myocardial infarction
I26.02-I26.09	Pulmonary embolism with acute cor pulmonale
I26.92-I26.99	Pulmonary embolism without acute cor pulmonale
I50.1-I50.9	Heart failure
I63.30-I63.39, I63.6	Cerebral infarction due to thrombosis of cerebral arteries and cerebral venous thrombosis
I63.40-I63.49	Cerebral infarction due to embolism of cerebral arteries

1–10 of 26

1/3

ICD-10 codes not covered for indications listed in CPBICD-10Not Covered

A40.00-A40.9	Streptococcal sepsis
A41.01-A41.49	Other sepsis
C49.0-C49.9	Malignant neoplasm of other connective and soft tissue [metastatic synovial sarcoma]
C50.011-C50.929	Malignant neoplasm of breast
D57.00-D57.02	Hb-SS disease with crisis
D57.211-D57.219	Sickle-cell/Hb-C disease with crisis
D57.811-D57.819	Other sickle-cell disorders with crisis
D69.51-D69.59	Secondary thrombocytopenia
H33.001-H33.8	Retinal detachments and breaks
I73.00-I73.01	Raynaud’s syndrome

1–10 of 18

1/2

CPT and other procedure codes related to CPBCPT

27120	Acetabuloplasty
27122	Acetabuloplasty; resection, femoral head
27125	Hemiarthroplasty, hip, partial
27130	Total hip arthroplasty
27132	Conversion to total hip arthroplasty
27134	Revision of total hip arthroplasty; both components
27137	Acetabular component only
27138	Femoral component only
27230-27236, 27267-27269	Treatment of femoral fracture
27447	Total knee arthroplasty

1–10 of 21

1/3

HCPCS codes covered for ArgatrobanHCPCSCovered

J0883	Injection, argatroban, 1 mg (for non-esrd use)
J0884	Injection, argatroban, 1 mg (for esrd on dialysis)
J0891	Injection, argatroban (accord), not therapeutically equivalent to J0883, 1 mg (for non-esrd use)
J0892	Injection, argatroban (accord), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis)
J0898	Injection, argatroban (auromedics), not therapeutically equivalent to J0883, 1 mg (for non-esrd use)
J0899	Injection, argatroban (auromedics), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis)

ICD-10 codes covered for Argatroban if selection criteria are metICD-10Covered

D75.821-D75.829

Heparin induced thrombocytopenia (HIT)

ICD-10 codes not covered for Argatroban (not all-inclusive)ICD-10Not Covered

C00.0-C96.9	Malignant neoplasms (general exclusion list)
G46.0-G46.8	Vascular syndromes of brain in cerebrovascular diseases
I24.9	Acute ischemic heart disease, unspecified [acute coronary syndrome]
I65.01-I66.9	Occlusion and stenosis of precerebral and cerebral arteries [stroke]
J80	Acute respiratory distress syndrome
K55.011-K55.069	Acute vascular disorders of intestine [acute superior mesenteric venous thrombosis]
T82.817+, T82.827+, T82.837+, T82.847+, T82.857+, T82.867+, T82.897+, T82.9xx+	Other specified complications of cardiac device, implant, and graft [prevention of in-stent re-stenosis]
Z95.811	Presence of heart assist device [ventricular assist device]

No procedural or reimbursement codes listed in this partmixed

No codes listed

Provider Actions & Billing Guidance

Documentation Required

Adhere to listed medical necessity criteria

Adhere to listed medical necessity criteria. Document indication and clinical rationale when using LMWHs or thrombin inhibitors, including but not limited to: major orthopedic or abdominal-pelvic cancer surgery (note extended prophylaxis durations where applicable), pregnancy-associated thrombotic conditions or antiphospholipid syndrome, cancer-associated VTE (initial and continued therapy), and heparin-induced thrombocytopenia (HIT).

Major orthopedic surgery (hip/knee)
Major abdominal-pelvic surgery for cancer (consider extended 4-week prophylaxis)
Pregnancy thrombotic conditions and antiphospholipid syndrome
Cancer-associated VTE (initial 5–10 days and continued ≥6 months; consider indefinite anticoagulation for selected patients with active/metastatic cancer)
Heparin-induced thrombocytopenia (HIT) — use alternative agents such as argatroban

Background & Evidence Summary

Background: LMWHs are subcutaneous heparin fragments (molecular weight ~4,000–9,000 daltons) that offer advantages over UFH in selected settings, including more predictable anticoagulant effects, less monitoring, and suitability for outpatient/home treatment; LMWHs are preferred in many cancer-associated VTE indications per ASCO and are favored over UFH for several indications. Argatroban is a parenteral direct thrombin inhibitor indicated for prophylaxis/treatment of thrombosis in HIT and for patients with or at risk for HIT undergoing PCI; it requires dilution to 1 mg/mL and weight- and indication-based infusion dosing. The policy notes pregnancy and pediatric considerations (LMWH advantages in pregnancy; pediatric indications from age ≥2 months for selected uses), and documents that several agents have been discontinued in the U.S. (Innohep/tinzaparin, Orgaran/danaparoid, Refludan/lepirudin, Iprivask/desirudin).

Evidence Source	Key Finding or Recommendation
ASCO recommendations (ASCO guideline updates)	LMWH preferred for cancer-associated VTE for initial and continuing treatment; routine outpatient prophylaxis not recommended except for select high-risk patients (e.g., thalidomide/lenalidomide); perioperative prophylaxis ≥7–10 days after major cancer surgery
TIMI / ESSENCE trials (unstable angina/non-Q-wave MI)	LMWH (e.g., enoxaparin) reduced early ischemic outcomes vs UFH and is effective in unstable angina/non-Q-wave MI without increased major bleeding in early phase
Cochrane reviews (van Dongen/van Dougen 2005; Bhutia & Wong 2013)	Once-daily LMWH regimens are generally as effective and safe as twice-daily for initial VTE treatment, though CIs permit possible differences in recurrence risk; pooled evidence supports comparable safety/effectiveness
Camporese et al. (Knee arthroscopy RCT)	7-day LMWH reduced composite endpoint vs compression stockings (3-month incidence 0.9% vs 3.2%; p=0.005) — benefit mainly in meniscectomy patients
International Myeloma Working Group / Palumbo et al. (2008) guidance	For myeloma patients on thalidomide/lenalidomide: aspirin for ≤1 risk factor; LMWH (enoxaparin 40 mg/day equivalent) recommended for ≥2 risk factors or concurrent high-dose dexamethasone/doxorubicin
ACCP / surgical duration recommendations (ACCP 8th/9th excerpts)	High-risk non-orthopedic cancer surgery: LMWH up to 28 days; hip fracture/arthroplasty: minimum 10–14 days with suggestion up to 35 days; total hip/knee: minimum 10–14 days (LMWH Grade 1B)
Cochrane & meta-analyses for lower-leg immobilization and ankle/foot trauma (Testroote/Zee; Hickey)	LMWH reduced DVT incidence versus no prophylaxis (OR ~0.45–0.49); moderate-quality evidence for reduced DVT; symptomatic PE effect less clear
COVID-19 LMWH vs UFH meta-analyses and RCTs (Alsagaff; Giossi; Lopes; Sadeghipour)	Observational meta-analyses associate LMWH with lower in-hospital mortality vs UFH; RCTs show therapeutic anticoagulation may not improve outcomes and can increase bleeding in hospitalized COVID-19 patients — prophylactic dosing recommended for hospitalized patients
ECMO systematic review & DTI analyses (M'Pembele et al. 2022; ECMO review)	DTIs (argatroban/bivalirudin) associated with lower mortality, major bleeding, and pump thrombosis vs heparin in retrospective studies; certainty very low — suggest DTI as alternative pending RCTs
Desirudin RCTs (Eriksson trials) and Cochrane DTI review	Desirudin reduced proximal and overall DVT versus enoxaparin and UFH in THR trials; pooled DTI data show comparable VTE prevention but higher bleeding and higher all-cause mortality reported in some DTI studies
Digital replantation & microvascular surgery Cochrane updates (Chen et al.; Lin et al.)	Multiple small RCTs found no clear benefit of LMWH over UFH for replantation success; limited/low-quality evidence with some lower bleeding with LMWH
PVST after splenectomy meta-analysis (Yang & Liu 2020)	LMWH associated with lower portal vein system thrombosis incidence post-splenectomy in pooled studies, though study limitations and regional bias noted

Definitions

Term	Definition
LMWH	Low-molecular-weight heparins: fragments of unfractionated heparin producing anticoagulation when administered subcutaneously (examples: enoxaparin, dalteparin, tinzaparin, nadroparin); exhibit anti‑Factor Xa and variable anti‑IIa activity
UFH	Unfractionated heparin: standard heparin preparations used for anticoagulation with different pharmacokinetics and monitoring requirements compared with LMWH
HIT	Heparin-induced thrombocytopenia / heparin-induced thrombocytopenia and thrombosis syndrome: immune‑mediated adverse reaction to heparin associated with thrombocytopenia and thrombosis
VTE	Venous thromboembolism: clinical spectrum that includes deep vein thrombosis (DVT) and pulmonary embolism (PE)
DTI	Direct thrombin inhibitor: agents that directly inhibit thrombin (e.g., argatroban, bivalirudin, desirudin, lepirudin); used for HIT and selected procedural anticoagulation
DOAC	Direct oral anticoagulant: oral agents targeting thrombin or Factor Xa (examples cited: dabigatran, apixaban, rivaroxaban, edoxaban) used for VTE and stroke prevention
VKA	Vitamin K antagonists: oral anticoagulants such as warfarin that inhibit vitamin K–dependent clotting factors; INR monitoring required (target usually 2–3)
PVST	Portal vein system thrombosis: thrombosis involving portal, splenic, or mesenteric veins; risk after splenectomy addressed in meta-analyses
PVR	Proliferative vitreoretinopathy: retinal scarring complication after retinal detachment; studies evaluated combined 5‑FU and LMWH infusion to prevent PVR
SGA	Small-for-gestational-age infant: defined in cited trials as less than the 5th customized birth‑weight percentile (or less than 10th percentile in other studies), used as outcome in preeclampsia/pregnancy analyses

Revision History

1999-08-11Effective Date

Policy effective

2023-05-16Last Review

Last review

2024-03-28Next ReviewLatest

Next review planned